A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Phase 1/2
50
about 5.6 years
0.0833333333333333–17
17 sites in CA, CO, CT +13
About this study
This trial is testing a treatment called patritumab deruxtecan, an antibody-drug conjugate, in children with relapsed or refractory solid tumors like hepatoblastoma or rhabdomyosarcoma. The goal is to learn about the safety and how the treatment works in these young patients.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Patritumab Deruxtecan
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part 1 and Part 2: Objective Response Rate (ORR), Part 1: AUC of DXd in plasma, Part 1: AUC of anti-HER3 antibody-conjugated DXd (anti-HER3-ac-DXd) in plasma, Part 1: Area Under the Curve (AUC) of total anti-HER3 antibody liquid chromatography-mass spectrometry (LC-MS) in plasma, Part 1: Cmax of DXd in plasma, Part 1: Cmax of anti-HER3-ac-DXd in plasma, Part 1: Maximum Concentration (Cmax) of anti-HER3 antibody LC-MS in plasma, Part 1: Percentage of Participants Who Discontinue Study Treatment Due to an AE
Secondary: Part 1 and Part 2: Disease Control Rate (DCR), Part 1 and Part 2: Duration of Response (DOR), Part 1 and Part 2: Overall Survival (OS), Part 1 and Part 2: Progression-free Survival (PFS), Part 2: AUC of DXd in plasma, Part 2: AUC of anti-HER3-ac-DXd in plasma, Part 2: AUC of total anti-HER3 antibody LC-MS in plasma, Part 2: Cmax of DXd in plasma
Oncology